← Leaderboards
Ken-Ichiro Fukuchi
University Of Alabama At Birmingham
$10,550,454
Attributed
$10,550,454
Total exposure
17
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $719.5K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,550,454 · 17
By mechanism
R01$5,690,269 · 3
R21$4,588,435 · 11
R41$200,000 · 2
R03$71,750 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseBrainDepositionMouse ModelSenile PlaquesPlayEtiologyImmunePathogenesisS Disease ModelNeurofibrillary TanglesAnimal ModelCerebrumMediatingImmune ResponseProductionDementiaCellsBehavioralCytokineCognitive FunctionMicrogliaInflammation
Grant awards (40)
Role of MyD88 signaling in systemic inflammation and Alzheimer disease$486,204
R01 · FY2025 · AG · contact PI
Role of MyD88 signaling in systemic inflammation and Alzheimer disease$506,127
R01 · FY2024 · AG · contact PI
Role of MyD88 signaling in systemic inflammation and Alzheimer disease$501,330
R01 · FY2023 · AG · contact PI
Role of MyD88 signaling in systemic inflammation and Alzheimer disease$469,350
R01 · FY2022 · AG · contact PI
Role of MyD88 signaling in systemic inflammation and Alzheimer disease$464,553
R01 · FY2021 · AG · contact PI
Modulation of innate immunity in Alzheimer disease$239,850
R21 · FY2020 · AG · contact PI
Altering immune tolerance in Alzheimer disease$239,850
R21 · FY2020 · AG · contact PI
Altering immune tolerance in Alzheimer disease$199,875
R21 · FY2019 · AG · contact PI
Modulation of innate immunity in Alzheimer disease$199,875
R21 · FY2019 · AG · contact PI
Role of blood-brain barrier interleukin-17 receptor A in Alzheimer disease$239,850
R21 · FY2018 · AG · contact PI
Role of extracellular vesicles in the high-fat diet-induced risk of Alzheimer disease$239,850
R21 · FY2018 · AG · contact PI
Role of diet-induced miR-34a in Alzheimer disease and dementia$239,850
R21 · FY2018 · AG · contact PI
Role of diet-induced miR-34a in Alzheimer disease and dementia$199,875
R21 · FY2017 · AG · contact PI
Role of extracellular vesicles in the high-fat diet-induced risk of Alzheimer disease$199,875
R21 · FY2017 · AG · contact PI
Role of blood-brain barrier interleukin-17 receptor A in Alzheimer disease$199,875
R21 · FY2017 · AG · contact PI
Role of microRNAs as modulators of neuroinflammation in Alzheimer disease$239,825
R21 · FY2016 · AG · contact PI
Role of microRNAs as modulators of neuroinflammation in Alzheimer disease$199,750
R21 · FY2015 · AG · contact PI
Role of the MyD88-independent pathway in Alzheimers disease$239,250
R21 · FY2014 · AG · contact PI
Innate immunity in Alzheimer's disease: Role of toll-like receptor signaling$289,425
R01 · FY2013 · AG · contact PI
Role of the MyD88-independent pathway in Alzheimers disease$199,375
R21 · FY2013 · AG · contact PI
Innate immunity in Alzheimer's disease: Role of toll-like receptor signaling$306,269
R01 · FY2012 · AG · contact PI
Innate immunity in Alzheimer's disease: Role of toll-like receptor signaling$306,269
R01 · FY2011 · AG · contact PI
Catalytic and non-catalytic Ig gene delivery for Alzheimer's disease$192,408
R21 · FY2011 · AG · contact PI
Innate immunity in Alzheimer's disease: Role of toll-like receptor signaling$318,632
R01 · FY2010 · AG · contact PI
Catalytic and non-catalytic Ig gene delivery for Alzheimer's disease$166,813
R21 · FY2010 · AG · contact PI
Innate immunity in Alzheimer's disease: Role of toll-like receptor signaling$321,850
R01 · FY2009 · AG · contact PI
Statins for Alzheimer's disease immunotherapy$200,175
R21 · FY2009 · AG · contact PI
Therapeutic delivery of single chain antibody for Alzheimer's disease$230,790
R21 · FY2008 · EY · contact PI
AAV-mediated muscle-directed gene transfer for Alzheimer's disease$193,673
R21 · FY2008 · AG · contact PI
Statins for Alzheimer's disease immunotherapy$166,813
R21 · FY2008 · AG · contact PI
Therapeutic delivery of single chain antibody for Alzheimer's disease$196,250
R21 · FY2007 · EY · contact PI
AAV-mediated muscle-directed gene transfer for Alzheimer's disease$164,688
R21 · FY2007 · AG · contact PI
Adenovirus vectored vaccines for Alzheimer's disease$100,000
R41 · FY2007 · AG · contact PI
Alzheimer Vaccines: Noninvasive Vaccination by DNA-Base*$372,260
R01 · FY2005 · NS
Alzheimer Vaccines: Noninvasive Vaccination by DNA-Base*$334,390
R01 · FY2004 · NS
Alzheimer Vaccines: Noninvasive Vaccination by DNA-Base*$334,390
R01 · FY2003 · NS
Alzheimer Vaccines: Noninvasive Vaccination by DNA-Base*$334,390
R01 · FY2002 · NS
Skin-patch Vaccination against Alzheimer's Disease$100,000
R41 · FY2002 · AG
Alzheimer Vaccines: Noninvasive Vaccination by DNA$344,830
R01 · FY2001 · NS
Targeted Mouse Models of Alzheimer Disease$71,750
R03 · FY2001 · AG